Point72 Asset Management L.P. Cuts Stock Position in Cryoport, Inc. (NASDAQ:CYRX)

Point72 Asset Management L.P. cut its stake in shares of Cryoport, Inc. (NASDAQ:CYRX - Free Report) by 16.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 352,680 shares of the company's stock after selling 67,220 shares during the quarter. Point72 Asset Management L.P. owned approximately 0.71% of Cryoport worth $2,744,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Cadian Capital Management LP grew its position in shares of Cryoport by 14.1% during the fourth quarter. Cadian Capital Management LP now owns 4,927,027 shares of the company's stock worth $38,332,000 after buying an additional 609,021 shares in the last quarter. Millennium Management LLC boosted its holdings in Cryoport by 11.0% in the fourth quarter. Millennium Management LLC now owns 4,139,869 shares of the company's stock valued at $32,208,000 after purchasing an additional 409,353 shares in the last quarter. Deutsche Bank AG boosted its holdings in Cryoport by 0.9% in the fourth quarter. Deutsche Bank AG now owns 1,397,121 shares of the company's stock valued at $10,870,000 after purchasing an additional 12,864 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Cryoport by 8.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 850,216 shares of the company's stock valued at $6,615,000 after purchasing an additional 63,301 shares in the last quarter. Finally, LPL Financial LLC boosted its holdings in Cryoport by 1,366.1% in the fourth quarter. LPL Financial LLC now owns 436,766 shares of the company's stock valued at $3,398,000 after purchasing an additional 406,976 shares in the last quarter. 92.90% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Cryoport

In other news, CEO Jerrell Shelton sold 4,620 shares of the company's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $6.29, for a total transaction of $29,059.80. Following the completion of the sale, the chief executive officer now owns 765,399 shares in the company, valued at $4,814,359.71. This represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold 19,830 shares of company stock worth $118,353 over the last 90 days. 10.00% of the stock is currently owned by insiders.

Cryoport Stock Performance

NASDAQ CYRX traded down $0.18 on Friday, reaching $6.04. The stock had a trading volume of 253,099 shares, compared to its average volume of 543,684. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. Cryoport, Inc. has a 12-month low of $4.58 and a 12-month high of $11.64. The business's 50-day moving average price is $5.93 and its 200 day moving average price is $6.82. The stock has a market cap of $302.83 million, a P/E ratio of -1.79 and a beta of 1.92.

Cryoport (NASDAQ:CYRX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. The company had revenue of $41.04 million during the quarter, compared to analysts' expectations of $56.19 million. As a group, equities analysts expect that Cryoport, Inc. will post -0.99 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on CYRX shares. Morgan Stanley lowered their price target on Cryoport from $8.00 to $7.00 and set an "equal weight" rating for the company in a report on Monday, May 5th. UBS Group upped their price target on Cryoport from $10.00 to $11.00 and gave the company a "buy" rating in a report on Tuesday, April 1st. Guggenheim reaffirmed a "buy" rating and issued a $10.00 price target on shares of Cryoport in a report on Wednesday, April 16th. Needham & Company LLC reaffirmed a "buy" rating and issued a $11.00 price target on shares of Cryoport in a report on Thursday, May 8th. Finally, Roth Mkm reiterated a "buy" rating and issued a $15.00 price objective on shares of Cryoport in a research note on Tuesday, April 1st. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Cryoport currently has an average rating of "Moderate Buy" and a consensus target price of $11.00.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.